Comments
Ahmedabad-based Cadila Healthcare (Zydus Cadila) today announced that the company has received the final approval from the US drugs regulator, US Food and Drug Administration (USFDA) to market a drug useful for treatment arthritis.
In a statement on Thursday, Cadila informed, “ The company has received final approval from the US drugs regulator US Food and Drug Administration (USFDA) to market Etodolac Extended-release Tablets USP, 400 mg, 500 mg, and 600 mg. The drug is prescribed for treatment of juvenile arthritis, rheumatoid arthritis and osteoarthritis.”
The group now has 88 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04, it added.
Cadila Healthcare shares ended almost flat on the stock exchanges on Thursday. The stock ended at Rs 809.15, down by 0.25 per cent on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.